Results 21 to 30 of about 25,779 (213)

Vaccination with virus-like particles containing hemagglutinin protects the lungs of mice with postifluenza bacterial pneumonia: virological, microbiological and clinical data

Вопросы вирусологии, 2020
Introduction. Influenza is a severe viral disease, a frequent complication of which is a secondary bacterial pneumonia. Influenza vaccines prevent secondary bacterial complications.
I. N. Falynskova, A. Yu. Egorov, A. V. Poddubikov, N. O. Vartanova, N. P. Kartashova, E. A. Glubokova, V. A. Mkhitarov, D. S. Dzhalilova, O. V. Makarova, I. A. Leneva   +9 more
doaj   +1 more source

Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. [PDF]

PLoS ONE, 2011
BACKGROUND: Although DNA plasmid and virus-like particle (VLP) vaccines have been individually tested against highly pathogenic avian influenza (HPAI) H5N1 viruses, the combination of both vaccines into a heterologous prime-boost strategy against HPAI ...
Heng Ding, Cheguo Tsai, Ramona Alikiiteaga Gutiérrez, Fan Zhou, Philippe Buchy, Vincent Deubel, Paul Zhou   +6 more
doaj   +1 more source

The safety of attenuated and recombinant nasal influenza vaccines in terms of the development of secondary bacterial superinfection

Журнал микробиологии, эпидемиологии и иммунобиологии, 2019
Introduction. Influenza is a severe viral disease. The most common post-influenza complication is pneumonia. Earlier, we developed an experimental mouse model of viralbacterial pneumonia induced by successive infection with influenza virus and St. aureus,
N. R. Makhmudova, I. A. Leneva, N. V. Larionova, A. V. Poddubikov, I. N. Falynskova, N. P. Kartashova, O. A. Svitich   +6 more
doaj   +1 more source

Pigs Immunized with the Virus-like Particle Vaccine Are Protected against the Hepatitis E-3 Virus

Vaccines, 2021
In this study, we generated the HEV virus-like particle (VLP) vaccine expressing 239 amino acids (367–605 aa) of the HEV-3 ORF2 using the baculovirus expression system.
Hyeon-Jeong Go, Byung-Joo Park, Hee-Seop Ahn, Dong-Hwi Kim, Da-Yoon Kim, Jae-Hyeong Kim, Joong-Bok Lee, Seung-Yong Park, Chang-Seon Song, Sang-Won Lee, Yang-Kyu Choi, In-Soo Choi   +11 more
doaj   +1 more source

Transdermal Vaccination with the Matrix-2 Protein Virus-like Particle (M2e VLP) Induces Immunity in Mice against Influenza A Virus

Vaccines, 2021
In this study, our goal was to utilize the extracellular domain matrix-2 protein virus-like particle (M2e VLP) that has been found to be highly conserved amongst all strains of influenza and could serve as a potential vaccine candidate against influenza.
Kimberly Braz Gomes, Sucheta D’Sa, Grace Lovia Allotey-Babington, Sang-Moo Kang, Martin J. D’Souza   +4 more
doaj   +1 more source

Promotion of Cellular and Humoral Immunity against Foot-and-Mouth Disease Virus by Immunization with Virus-Like Particles Encapsulated in Monophosphoryl Lipid A and Liposomes

Vaccines, 2020
Virus-like particles (VLPs) have emerged as promising vaccine candidates against foot-and-mouth disease (FMD). However, such vaccines provide a relatively low level of protection against FMD virus (FMDV) because of their poor immunogenicity.
Woo Sik Kim, Yong Zhi, Huichen Guo, Eui-Baek Byun, Jae Hyang Lim, Ho Seong Seo   +5 more
doaj   +1 more source

Dry Formulation of Virus-Like Particles in Electrospun Nanofibers

Vaccines, 2021
Biologics can be combined with liquid polymer materials and electrospun to produce a dry nanofibrous scaffold. Unlike spray-drying and freeze-drying, electrospinning minimizes the physiological stress on sensitive materials, and nanofiber mat properties ...
Sasheen Dowlath, Katrin Campbell, Farah Al-Barwani, Vivienne L. Young, Sarah L. Young, Greg F. Walker, Vernon K. Ward   +6 more
doaj   +1 more source

Major findings and recent advances in virus-like particle (VLP)-based vaccines. [PDF]

, 2017
Virus-like particles (VLPs) have made giant strides in the field of vaccinology over the last three decades. VLPs constitute versatile tools in vaccine development due to their favourable immunological characteristics such as their size, repetitive ...
Mohsen, Mona, Mona O. Mohsen, Lisha Zha, Zha, Lisha, Gustavo Cabral-Miranda, Bachmann, Martin, Cabral-Miranda, Gustavo, Martin F. Bachmann   +7 more
core   +1 more source

Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV

Viruses, 2019
Human cytomegalovirus (HCMV) infects more than 70% of the human population worldwide. HCMV is responsible for high morbidity and mortality in immunocompromised patients and remains the leading viral cause of congenital birth defects. Despite considerable
Michela Perotti, Laurent Perez
doaj   +1 more source

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine

iScience
Summary: Continuing emergence of variants of concern resulting in reduced SARS-CoV-2 vaccine efficacy necessitates additional prevention strategies. The structure of VLPCOV-01, a lipid nanoparticle-encapsulated, self-amplifying RNA COVID-19 vaccine with ...
Masayuki Aboshi, Kenta Matsuda, Daisuke Kawakami, Kaoru Kono, Yoko Kazami, Takashi Sekida, Mai Komori, Amber L. Morey, Shigeru Suga, Jonathan F. Smith, Takasuke Fukuhara, Yasumasa Iwatani, Takuya Yamamoto, Nobuaki Sato, Wataru Akahata   +14 more
doaj   +1 more source